Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
| Revenue (TTM) | $48.48B |
| Gross Profit (TTM) | $34.90B |
| EBITDA | $18.97B |
| Operating Margin | 33.00% |
| Return on Equity | 38.70% |
| Return on Assets | 10.70% |
| Revenue/Share (TTM) | $23.82 |
| Book Value | $9.83 |
| Price-to-Book | 6.37 |
| Price-to-Sales (TTM) | 2.68 |
| EV/Revenue | 3.376 |
| EV/EBITDA | 10.91 |
| Quarterly Earnings Growth (YoY) | 9.20% |
| Quarterly Revenue Growth (YoY) | 2.60% |
| Shares Outstanding | $2.04B |
| Float | $2.04B |
| % Insiders | 0.08% |
| % Institutions | 83.80% |
Volatility is currently contracting
BMY heads into Q2 earnings with growth drugs driving momentum as legacy products decline, setting the stage for a closely watched earnings report.
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and development operations.
PRINCETON, N.J.--(BUSINESS WIRE)---- $bmy--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMY and any ticker you trade — then tracks every position and per-strategy win rate.
